Natalia Barajas Castrellon: FRONTIER2 Results Show Potential for Prophylactic Therapy in Hemophilia A
Natalia Barajas Castrellon, Rared Associate Director Medical and Marketing at Novo Nordisk, reposted from Novo Nordisk on LinkedIn:
”New data from Novo Nordisk in hemophilia A, published in NEJM Group, reinforces the strategic direction of the portfolio.
The results highlight the potential of an investigational prophylactic therapy to reduce bleeding episodes across patient segments, including those with inhibitors – while enabling greater treatment individualization, a key driver of next-generation care models.
This builds on well-established progress in hemophilia, where advances in prophylaxis have materially improved quality of life and extended life expectancy toward that of the general population.”
Novo Nordisk shared on LinkedIn about a recent article by Maria Elisa Mancuso et al, published in NEJM, adding:
”Results from Novo Nordisk’s hemophilia research published in NEJM Group highlights the potential of an investigational preventive bleed treatment option to help people living with hemophilia A, with or without inhibitors.
Learn more in the press release.”
Title: Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors
Authors: Maria Elisa Mancuso, Anthony K.C. Chan, Chandrakala Shanmukhaiah, Chuhl Joo Lyu, Joanna Zdziarska, Johnny Mahlangu, Lize F.D. van Vulpen, Pratima Chowdary, Renchi Yang, Steven R. Lentz, Tadashi Matsushita, Wan Hui Ong Clausen, Ilgiz Rakhmatullin, Johannes Oldenburg for the FRONTIER2 Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda